Compare GMAB & SMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | SMCI |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 20.1B |
| IPO Year | N/A | 2006 |
| Metric | GMAB | SMCI |
|---|---|---|
| Price | $26.01 | $21.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 18 |
| Target Price | ★ $39.81 | $35.81 |
| AVG Volume (30 Days) | 1.6M | ★ 36.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $2,484,929,000.00 |
| Revenue This Year | $17.80 | $90.64 |
| Revenue Next Year | $14.86 | $19.76 |
| P/E Ratio | ★ $1.90 | $25.56 |
| Revenue Growth | N/A | ★ 11.68 |
| 52 Week Low | $17.24 | $19.48 |
| 52 Week High | $35.43 | $62.36 |
| Indicator | GMAB | SMCI |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 32.14 |
| Support Level | $24.95 | $19.48 |
| Resistance Level | $33.75 | $33.47 |
| Average True Range (ATR) | 0.56 | 1.51 |
| MACD | 0.12 | -0.85 |
| Stochastic Oscillator | 37.22 | 16.99 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.